Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwAL 2022 | Novel targets, treatments, and combinations in AML

David Sallman, Richard Stone and Thomas Cluzeau • 29 Sep 2022
iwAL 2022
Acute Myeloid Leukemia Leukemia Antibodies Azacitidine Eprenetapopt Magrolimab Venetoclax

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discuss challenges in acute myeloid leukemia (AML), including TP53-mutated disease, novel combinations being explored, and more. This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from David Sallman

Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
7:19
Phase IIa trial of ofirnoflast, a first-in-class allosteric NEK7 inhibitor, in ESA-refractory LR-MDS
David Sallman • 1 Oct 2026
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
4:14
Lessons from Phase I KITE-222: antigen escape, expansion, and the future of CAR-T in AML
David Sallman • 1 Oct 2026
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
4:28
Lessons from Phase III ENHANCE: TP53, transplant, and MRD in future HR-MDS combination trials
David Sallman • 1 Oct 2026
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
17:01
Emerging immunotherapy strategies in AML: CAR-T, NK cells and T-cell engagers
David Sallman et al. • 20 Sep 2026

More from Richard Stone

Evaluating the use of MRD status to guide post-remission therapy in AML
1:20
Evaluating the use of MRD status to guide post-remission therapy in AML
Richard Stone • 28 Feb 2026
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
1:40
The safety and efficacy of adding venetoclax to intensive chemotherapy for patients with AML
Richard Stone • 28 Feb 2026
Approaches to managing FLT3-mutant AML
12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
Marina Konopleva et al. • 1 Oct 2024

More from Thomas Cluzeau

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
1:28
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
Thomas Cluzeau • 13 Jun 2026
Recent advances in frontline treatment approaches for patients with LR-MDS
2:17
Recent advances in frontline treatment approaches for patients with LR-MDS
Thomas Cluzeau • 13 Jun 2026
Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
2:38
Selecting patients with AML for transplant: key considerations & the role of enhanced MRD monitoring
Thomas Cluzeau • 13 Jun 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals